Yingzhe Liu

Ms. Yingzhe Liu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Journal of Urology
Verified
Journal Article
Open access
SSSarah Sandlow
Sarah Sandlow
SCSamuel Carbunaru
Samuel Carbunaru
ZSZequn Sun
Zequn Sun
BOBernice Ofori
Bernice Ofori
YLYingzhe Liu
Yingzhe Liu
AMAdam B. Murphy
Adam B. Murphy
Prostate Imaging Reporting and Data System (PIRADS) v2.1 scoring with multiparametric MRI (mpMRI) has a pooled 90% negative predictive value (NPV). PSA density (PSAD) ≤0.15ng/ml/cm3 has been shown to enhance mpMRI's NPV in non-Black men. Populations with higher disease prevalence are known to have lower NPVs. Given that Black men have higher PCa prevalence, we evaluate sensitivity and NPV of mpMRI in Black vs. non-Black men to assess possible mpMRI performance differences. As an exploratory objective, we investigate PSAD thresholds providing ≥90% sensitivity in Black men. We prospectively recruited Black and non-Black men referred to outpatient urology clinics for abnormal PSA or prostate exam in three similar biomarker validation studies from 2017-23 before MRI-informed diagnostic prostate biopsy. We combined the research cohorts with a retrospective clinical cohort of clinically similar Black and non-Black men from one academic institution who also underwent mpMRIs and MRI-informed biopsies. MRIs were scored using PIRADS version 2.0 or 2.1. Our analysis included 286 Black men and 965 non-Black men with PSA ≤15.0ng/ml. PIRADS <3 had an NPV of 77.1% versus 87.6% and a sensitivity of 90.7% vs. 96.3% for GG2-5 PCa in Black versus non-Black men, respectively (both p <0.05). Using PSAD ≥0.09 for Black men with PIRADS 1-2 lesions increased sensitivity to 92.9%. PIRADS <3 has a lower NPV and sensitivity in Black men. For negative prostate MRIs, PSAD ≥0.09 may be a better threshold for safe biopsy deferral in Black men to maintain a ≥90% sensitivity.

30 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CVChetan Vakkalagadda
Chetan Vakkalagadda
DDDanielle Dressler
Danielle Dressler
ZSZequn Sun
Zequn Sun
JFJoseph Fuchs
Joseph Fuchs
YLYingzhe Liu
Yingzhe Liu
NMNisha A. Mohindra
Nisha A. Mohindra
Purpose: Broad-based molecular testing with next-generation sequencing (NGS) is now the standard of care in advanced non-small cell lung cancer (NSCLC). Two approaches to molecular testing are (1) reflexive testing at pathologic NSCLC confirmation, often using an in-house molecular panel, and (2) send-out testing to private vendors, ordered by a clinician. This study explored the outcomes with reflex versus send-out testing. Methods: A retrospective chart review was conducted of patients diagnosed with de novo stage IV NSCLC in 2019 and 2020 at three hospitals in the same system, one academic hospital (Northwestern Memorial Hospital, or NMH) utilizing reflex, in-house NGS, and two community-based hospitals (Central DuPage Hospital, or CDH, and Delnor, or D) sending out tissue samples for testing. The outcomes assessed were the time from biopsy to results, biopsy to treatment, the incidence of first-line targetable mutations and the use of first-line targeted therapies, and overall survival. Results: In total, 191 patients met the inclusion criteria, 85 at NMH, 106 at CDH + D, and in total, 131 in 2019 and 60 in 2020. The time to results was significantly shorter with reflexive NGS when compared with send-out testing; the time to treatment was also shorter but not statistically significant. At CDH + D, the time to results was significantly shorter with a limited panel than with comprehensive testing, but the time to treatment was similar. NGS testing rates were 95% at NMH and 84.5% at CDH + D (p = 0.009), with 31.0% at NMH receiving 1L targeted therapies versus 20.8% at CDH + D (p = 0.08). In 2019, the median time from biopsy to treatment was 35 days at NMH and 38 days at CDH and Delnor; in 2020, time to treatment was 26 days and 37 days, respectively. Overall survival trended longer in 2020 relative to 2019 independent of site. Conclusion: Reflexive NGS testing is associated with a shorter time to actionable results and higher rates of first-line targetable mutations than send-out testing. In practices with send-out testing, limited panels had slightly faster turnaround times but no difference in time to treatment. If resources allow, reflexive NGS should be considered in healthcare systems for patients with NSCLC.

3 February 2025 in Thoracic Cancer
Verified
Journal Article
Open access
RDRichard Duan
Richard Duan
MKMichelle Kwan
Michelle Kwan
AKAvram Kordon
Avram Kordon
CHCarolyn J. Hu
Carolyn J. Hu
NVNisheka Vanjani
Nisheka Vanjani
LGLaila A. Gharzai
Laila A. Gharzai
Objectives: Stage III non‐small cell lung cancer (NSCLC) treatment remains challenging, with a multitude of treatment options available. We assessed Stage IIIA NSCLC outcomes by treatment received.Methods: We performed a single‐institution retrospective review of NSCLC patients with Stage IIIA disease treated January 01, 2010—March 01, 2022. Demographics, treatments, outcomes, and failure patterns were collected. Progression‐free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier analysis. Failure patterns were assessed for differences using chi‐square analysis.Results: Of 270 Stage III NSCLC patients, 134 had Stage IIIA disease with a median follow‐up of 29.9 months and a median age of 66 years (IQR 60–75). 66 (49.3%) patients were male, and 105 (78.4%) were current/former smokers (with 30 median pack‐years). Patients were treated with definitive radiation with/without chemotherapy (CRT; n = 77, 57.5%), surgery with neoadjuvant chemotherapy and/or radiation (Neoadj; n = 42, 31.3%), and surgery without neoadjuvant therapy (Surg; n = 15, 11.2%). Median PFS was 25.4 months (95% CI 12.5–42.6) for CRT, 22.6 months (95% CI 12.2–44.4) for Neoadj, and 22.8 months (95% CI 5.2‐NA) for Surg with no significant intergroup difference (p = 0.99). Median OS was 57.0 months (95% CI 37.4–77.5) for CRT, 51.5 months (95% CI 36.7–65.5) for Neoadj, and 35.3 months (95% CI 16.8‐NR) for Surg with no significant intergroup difference (p = 0.99).Conclusions: In this single institution retrospective study, we find no significant differences in PFS, OS, and failure patterns between patients with Stage IIIA NSCLC treated with definitive (chemo)radiation and surgery with or without neoadjuvant therapy. Further work in the immunotherapy era is needed.